What is the appropriate management of graft-versus-host disease (GVHD)?

Management of Graft-Versus-Host Disease (GVHD)

For steroid-refractory acute GVHD and steroid-refractory chronic GVHD, ruxolitinib is now the standard of care second-line therapy 1, 2.

Acute GVHD Management

First-Line Treatment

• Corticosteroids remain the recommended first-line systemic therapy for acute GVHD 2
• Use methylprednisolone 1-2 mg/kg/day for grade 2-4 acute GVHD
• For grade 2 acute GVHD with isolated skin or upper GI involvement only, consider lower steroid doses (0.5-1 mg/kg/day) 3
• The MAGIC grading scheme is the consensus standard for grading acute GVHD 2

Risk Stratification

Clinical tools and noninvasive blood-based biomarkers should be used to risk-stratify patients with newly diagnosed acute GVHD, allowing for potential treatment intensification in high-risk patients 2.

Second-Line Treatment (Steroid-Refractory Disease)

• Ruxolitinib is the standard second-line therapy for steroid-refractory acute GVHD 1, 2
• For pediatric patients specifically, remestemcel-L is recognized as an alternative standard 2
• Early administration of T-cell antibodies or TNF blockade may be considered in select cases 4

Third-Line Treatment

No consensus treatment exists for third-line therapy; management should be guided by institutional experience and available clinical trials 2.

Chronic GVHD Management

First-Line Treatment

• Corticosteroids (prednisone 1 mg/kg/day or equivalent) combined with a calcineurin inhibitor (cyclosporine or tacrolimus) for systemic chronic GVHD 5

Second-Line Treatment (Steroid-Refractory Disease)

Ruxolitinib is the new standard of care for steroid-refractory chronic GVHD 1. This represents a major update from previous recommendations.

Additional options include:

• Belumosudil - newly added as an available treatment option 1
• Rituximab - particularly effective for skin manifestations (60% ORR) and facilitates 75-86% steroid dose reduction; use 375 mg/m²/week for 4-8 weeks 6
• Pentostatin - shows activity with 38% ORR, though associated with renal toxicity and infections 6

Organ-Specific Considerations

For bronchiolitis obliterans syndrome (lung chronic GVHD), use the combination of fluticasone, azithromycin, and montelukast 3.

GVHD Prophylaxis

The landscape has shifted significantly with new evidence:

For Peripheral Blood Stem Cell Transplants from Unrelated Donors

Use either:

• Rabbit anti-thymocyte globulin (ATG) as standard prophylaxis, OR
• Post-transplantation cyclophosphamide (PTCy) 1

These approaches have dramatically improved safety with HLA-mismatched and matched donors, expanding the donor pool 7.

Standard Backbone Regimens

• Calcineurin inhibitor (cyclosporine or tacrolimus) PLUS methotrexate or mycophenolate mofetil remains standard 8
• Post-transplant cyclophosphamide has shown excellent results and is increasingly used across donor types 8, 7
• Newer agents include abatacept (checkpoint blockade) and sirolimus (mTOR inhibition) 7

Essential Supportive Care for ALL Patients with GVHD

Infection Prevention (Critical - Infection is the Leading Cause of Death)

• Initiate antimicrobial prophylaxis with escalating immunosuppression 6
• CMV surveillance is mandatory in appropriate patients given significant mortality risk 6
• Consider additional viral surveillance 6
• Avoid live vaccines in all patients on immunosuppression or with active GVHD 6
• COVID-19 revaccination starting 3 months post-transplant 6

Prophylactic Intravenous Immunoglobulin (IVIG)

Routine prophylactic IVIG is NOT recommended due to lack of clear benefit, increased risk of sinusoidal obstruction syndrome and thrombosis, and reduced vaccine efficacy 6.

Exceptions where IVIG may be considered:

• Umbilical cord blood transplant recipients
• Children with inherited/acquired B-cell deficiency disorders
• Patients with chronic GVHD and recurrent sinopulmonary infections 6

Hepatic Protection

Ursodiol prophylaxis should be considered to prevent hepatic complications including liver GVHD; it reduces bilirubin elevation, severe acute GVHD, GI GVHD, and improves survival 6.

Key Clinical Pitfalls

1. High-dose steroids carry significant infection risk - balance GVHD control with infectious complications, particularly viral and fungal 6
2. Rituximab response varies by organ - skin responds best (60%), while liver (29%) and lung (30%) show lower response rates 6
3. Steroid tapering must be gradual to avoid GVHD flares while minimizing toxicity 5
4. The goal is GVHD control while minimizing toxicity AND relapse risk - overly aggressive immunosuppression increases infection and relapse 5, 9